Innovation and Start-Up Center for Biotechnology (IZB) welcomes T-CURX GmbH

Martinsried near Munich, 21. December 2022 – The Innovation and Start-up Center for Biotechnology (IZB), one of the leading biotechnology centers in Europe, and home to about 50 biotech start-ups, today announced that T-CURX GmbH (T-CURX) has moved into the IZB with its Munich office. T-CURX is an early-stage biopharmaceutical company headquartered in the Innovation and Start-up Center Wuerzburg, Germany, developing personalized immunotherapies based on CAR-T cells for cancer indications of high medical need.

T-CURX has built a portfolio of proprietary and IP-protected CAR-T technologies that are centered around a novel Sleeping Beauty (SB) Transposon gene transfer technology, which is exclusively licensed to T-CURX from the University of Wuerzburg. The Company’s aim is to overcome current limitations of CAR-T cells therapies, lowering complexities and costs in manufacturing, thereby giving many more patients with both hematological malignancies and solid tumors access to these promising personalized medicines. T-CURX’s pipeline includes four programs, with the first candidate already in Phase I clinical development for Multiple Myeloma and a second CAR-T program in acute myeloid leukemia (AML) which will be ready for clinical trial application next year.

„Our innovative and scalable CAR-T technologies will give more patients the chance to benefit from CAR-T therapies. We are convinced that the inspiring atmosphere and diverse network at IZB will enhance our vision to establish our technology as the gold-standard in CAR-T cell therapies and support our future funding activities,” commented Dr. Ulf Grawunder, co-founder and CEO of T-CURX.

„We welcome T-CURX to our fast-growing biotechnology campus. I am pleased that another highly innovative start-up has chosen the IZB to develop its therapeutics pipeline and I am excited to see the Company’s future development,“ added Dr. Peter Hanns Zobel, Managing Director of the IZB.

About the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich
The Fördergesellschaft IZB, founded in 1995, operates the Innovation and Start-up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a leading biotechnology center. About 50 biotech companies with over 700 employees are currently based on 26,000 m2. Here, work is being done on developing drugs for the most serious diseases, such as cancer, Alzheimer’s and various autoimmune diseases. A key criterion for the success of the IZBs is the physical proximity to cutting-edge research on the Martinsried/Grosshadern campus and the Weihenstephan campus. The new infrastructure measures such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Elhardt chemistry college, the two kindergartens Bio Kids and Bio Kids2 as well as the two restaurants SEVEN AND MORE and THE BOWL Food Lounge are also location factors that are highly valued by the founders of the company. Successful companies that emerged from the IZB include Corimmun (today Janssen-Cilag), Coriolis, Exosome Diagnostics (bought by Bio-Techn), ibidi, Immunic Therapeutics, Medigene, Micromet (today Amgen), MorphoSys, Octopharma or Rigontec (now MSD). More information at www.izb-online.de

Press contact and image material requests:
Susanne Simon, Head of Press and Public Relations
Innovation and Start-up Center Biotechnology (IZB)
Am Klopferspitz 19, D-82152 Planegg-Martinsried,
Phone: +49 (0)89/55 279 48-17, E-mail: ed.enilno-bzi@nomis;
Website: www.izb-online.de

About T-CURX GmbH
T-CURX is a private German biopharmaceutical company headquartered in Wuerzburg, focused on identifying, developing and commercializing next generation CAR-T cell therapies in cancer indications of high medical need. The company´s proprietary CAR-T technologies were developed in the labs of co-founder Prof. Michael Hudecek at Universitätsklinikum Würzburg and are centered around a novel Sleeping Beauty (SB) Transposon gene transfer technology, which is exclusively licensed to T-CURX. T-CURX has a development pipeline of 4 CAR-T programs, the first product is in clinical development (Ph I), the second CAR-T program (novel target) will be ready for clinical trial application next year.

Additional proprietary technologies that will be leveraged in T-CURX’ developing CAR-T cell product pipeline include (i) the proprietary Matchmaker technology for optimized potency and efficacy of T-CURX’ CAR-T cell products and (ii) a proprietary safety-switch that allows to control the function of CAR-T cells after infusion into patients to improve the patient safety. For more information about T-CURX visit the website www.t-curx.com.

Contact T-CURX:

Ulf Grawunder, CEO
Am Klopferspitz 19
82152 Planegg
Email: moc.xruc-t@flu

 

Media contact:
Phone: +49-(0)-931-250-99-712
Email: moc.xruc-t@rp